Maytus Capital Management, LLC Bei Gene, Ltd. Transaction History

Maytus Capital Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$260.64 - $382.12 $3.13 Million - $4.59 Million	-12,000 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$221.31 - $316.61 $995,895 - $1.42 Million	-4,500 Reduced 27.27%	12,000 $3.1 Million
Q3 2020 Nov 04, 2020	BUY	$189.18 - $286.44 $3.12 Million - $4.73 Million	16,500 New	16,500 $4.73 Million

215

45.1M

76.5K

72.3K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $15B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Maytus Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Maytus Capital Management, LLC with notifications on news.